Related Experiment Video
Updated: Jun 15, 2026
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Amyloid-beta immunotherapy for Alzheimer's disease
1Center for Neurologic Diseases, Department of Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
CNS & Neurological Disorders Drug Targets
|March 9, 2010
Summary
Alzheimer's disease immunotherapy targeting amyloid-beta shows promise in reducing plaques and improving cognition in models. Refined active and passive vaccines are under investigation for safer, more effective Alzheimer's disease treatments.
Area of Science:
- Neuroscience
- Immunology
- Gerontology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia in the elderly.
- Current AD therapies offer symptomatic relief but do not alter disease progression.
- Amyloid-beta (Abeta) peptide is implicated in AD pathogenesis, making it a therapeutic target.
Purpose of the Study:
- To review the current status of Abeta immunotherapy for Alzheimer's disease.
- To discuss Abeta immunotherapy in both animal models and human trials.
- To explore the mechanisms of action for Abeta immunotherapy in AD.
Main Methods:
- Review of preclinical studies in animal models of AD.
- Analysis of human clinical trials, including both active and passive Abeta immunotherapy.
- Examination of reported outcomes such as amyloid burden reduction, cognitive function, and adverse events.
Main Results:
- Abeta immunotherapy demonstrated amyloid plaque reduction and cognitive improvement in animal models.
- An early human trial of active Abeta vaccine was halted due to meningoencephalitis.
- Some patients in the trial showed cognitive stabilization and plaque clearance, supporting further research.
Conclusions:
- Abeta immunotherapy holds potential for treating Alzheimer's disease, but safety and efficacy need optimization.
- Refinement of active and passive Abeta vaccines is crucial for developing safer and more effective AD therapies.
- Ongoing clinical trials are vital for advancing Abeta immunotherapy for Alzheimer's disease.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...